The Lancet. Respiratory medicine

The most recent articles from: Lancet Respir Med June 2018

Lancet Respir Med · Jun 2018

Multicenter Study

Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.

An inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations. ⋯ The European Organisation for Research and Treatment of Cancer and Pfizer.

read on… or just mark as read…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,706,642 articles already indexed!